Fake anti-malarials: start with the facts

Malaria Journal

Meeting Report

Benjamin K. Wilson¹  Heidi Hopkins²  Harparkash Kaur²  Debora Miranda²  David Schellenberg²  Siȃn Clarke²  Mirza Lalani²  Aline Plançon³  Souly Phanouvong⁴  Michael Deats⁵  Andrew McLoughlin⁶  Philippe Guérin⁷ 

[1] Intellectual Ventures Laboratory, Bellevue, WA, USA;London School of Hygiene and Tropical Medicine, WC1E 7HT, London, UK;Medical Product Counterfeiting and Pharmaceutical Crime Sub-Directorate, INTERPOL, Lyon, France;Promoting the Quality of Medicines Program, U.S. Pharmacopeial Convention, Rockville, MD, USA;SSFFC Surveillance and Monitoring, Safety and Vigilance, Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland;The Global Fund to Fight Aids, Tuberculosis and Malaria, Geneva, Switzerland;Worldwide Antimalarial Resistance Network (WWARN), University of Oxford, Oxford, UK;Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK;

关键词: Drug quality;    Falsified;    Substandard;    Artemisinin combination therapy;    Anti-malarials;    Degraded drugs;   

DOI  :  10.1186/s12936-016-1096-x

 received in 2015-12-24, accepted in 2016-01-10,  发布年份 2016

来源: Springer

【 摘 要 】

This meeting report presents the key findings and discussion points of a 1-day meeting entitled ‘Fake anti-malarials: start with the facts’ held on 28th May 2015, in Geneva, Switzerland, to disseminate the findings of the artemisinin combination therapy consortium’s drug quality programme. The teams purchased over 10,000 samples, using representative sampling approaches, from six malaria endemic countries: Equatorial Guinea (Bioko Island), Cambodia, Ghana, Nigeria, Rwanda and Tanzania. Laboratory analyses of these samples showed that falsified anti-malarials (<8 %) were found in just two of the countries, whilst substandard artemisinin-based combinations were present in all six countries and, artemisinin-based monotherapy tablets are still available in some places despite the fact that the WHO has urged regulatory authorities in malaria-endemic countries to take measures to halt the production and marketing of these oral monotherapies since 2007. This report summarizes the presentations that reviewed the public health impact of falsified and substandard drugs, sampling strategies, techniques for drug quality analysis, approaches to strengthen health systems capacity for the surveillance of drug quality, and the ensuing discussion points from the dissemination meeting.

【 授权许可】

CC BY   
© Kaur et al. 2016